Skip to content

Community-acquired Pneumonia in Buskerud County in Norway

Community-acquired Pneumonia: A Prospective Observational Study to Explore Etiology, Risk Factors and Potential Predictors for re- Admittance to Hospital and All-cause Mortality

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01563315
Enrollment
270
Registered
2012-03-26
Start date
2008-01-31
Completion date
2012-01-31
Last updated
2012-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Infections, Pneumonia

Keywords

Community-Acquired Infections, Pneumonia/microbiology, Pneumonia/diagnosis, Prognosis, Prospective Studies

Brief summary

The purpose of this study is to determine the etiology of community-acquired pneumonia, to assess risk factors and to investigate potential prognostic biomarkers of serious disease and fatal outcome.

Detailed description

Background: This project addresses an important challenge in international medicine: Pneumonia as the leading cause of death from infection in developed countries. Purpose: (A) Determine the etiology of CAP among adult hospitalized patients- especially the occurrence of mixed infections- by systematic implementation of combined conventional and new diagnostic methods. (B) Assess risk factors of CAP, such as COPD, congestive heart failure, smoking, malignancy etc., predictive of re-admittance to hospital and mortality. (C) Examine the prognostic value of potential predictors in relation to all-cause mortality in adult patients hospitalized with CAP. Design: Prospective observational study with inclusion of 270 adult patients during a 3-year period, who all required admission for pneumonia in a community hospital setting. Clinical and biochemical data was recorded longitudinally by inclusion, at stable clinical situation and after 6 weeks, and mortality and need for re-admission within 12 months. Patients were examined systematically, using modern research methods to explore relevant microbes. At all points, blood tests were sampled for clinical-chemical analysis, DNA, RNA and immunological analyses. Application: A translational research approach with the ambitions to elucidate new pathogenic mechanisms which could lead to new diagnostic tools and treatment modalities. This will possibly lead to less drug exposure and unnecessary hospitalization both of which have positive consequences for patients and medical care costs.

Interventions

None listed

Sponsors

Vestre Viken HF - Buskerud Hospital
CollaboratorUNKNOWN
Oslo University Hospital
CollaboratorOTHER
UMass Medical school, Massachusetts - USA
CollaboratorUNKNOWN
Vestre Viken Hospital Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* New infiltrate on chest X-ray and * Fever \> 38,0 by rectal measurement * at least one of these additional criteria: Cough +/- expectoration, dyspnoea, respiratory chest pain, crackles or reduced respiratory sounds. * Criteria must be present within 48 hours after admission

Exclusion criteria

* Patients \< 18 years * Non infectious cause of lung infiltration (tumors, embolism) * Bronchial obstruction (tumor, bronchiectasia) * Hospitalised more than 48 hours or discharged within the last 2 weeks

Design outcomes

Primary

MeasureTime frame
all cause mortalityone year

Secondary

MeasureTime frame
Re-admission to hospitalOne month

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026